Granulocytic sarcoma (GS) is a rare extra medullary solid tumour composed of immature myeloid cells. These tumours often display a greenish colour due to the enzymatic action of myeloperoxidase in the tumour cells. Hence, the term 'chloroma' was given to this lesion in 1853. GS commonly involves bone, periosteum, soft tissue, lymph node, and skin. Rare occurrences in muscle, meninges, breast, mediastinum, joints and ovary have been reported. Below-knee joint involvement in GS is unusual. We report a case of generalized cutaneous granulocytic sarcoma with ankle joint involvement who subsequently developed AML-M4.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Macroscopic Hematuria Revealing Bladder Myeloid Sarcoma in Acute Myeloid Leukemia.
Cureus
December 2024
Department of Hematology, Hôpital Universitaire de Bruxelles (HUB) Institut Jules Bordet, Brussels, BEL.
Acute myeloid leukemia (AML) can be presented with extramedullary manifestations, more frequently involving skin and rarely other sites, such as the urinary tract. We report the case of a 37-year-old male patient with a history of testicular cancer who presented to the emergency department with cytopenias and hematuria. Bone marrow analysis diagnosed AML (French-American-British(FAB) classificationM4 subtype, karyotype showing inv16).
View Article and Find Full Text PDFIntegrative analysis of Ewing's sarcoma reveals that the MIF-CD74 axis is a target for immunotherapy.
Cell Commun Signal
January 2025
Department of Musculoskeletal Tumor, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing, 100044, China.
Background: Ewing's sarcoma (EwS), a common pediatric bone cancer, is associated with poor survival due to a lack of therapeutic targets for immunotherapy or targeted therapy. Therefore, more effective treatment options are urgently needed.
Methods: Since novel immunotherapies may address this need, we performed an integrative analysis involving single-cell RNA sequencing, cell function experiments, and humanized models to dissect the immunoregulatory interactions in EwS and identify strategies for optimizing immunotherapeutic efficacy.
Kaleidoscopic Chloroma: An Unusual Case of Myeloid Sarcoma.
Cureus
December 2024
Radiology, Tata Main Hospital, Jamshedpur, IND.
We report a 37-year-old male patient who had nonbilious vomiting, no passage of flatus, and recurring abdominal pain. This patient had de novo intestinal myeloid sarcoma (MS), a rare and chameleonic presentation of acute leukemia of myeloid origin. The initial diagnostic evaluation suggested Koch's abdomen, and surgical excision of the bowel was performed with a clinical suspicion of Koch's or lymphoma.
View Article and Find Full Text PDFA Novel Disulfidptosis-Related Risk Signature for Prognostic Prediction in Patients With Ewing Sarcoma.
J Orthop Res
January 2025
Department of East Hospital Orthopaedic Trauma, Zibo Central Hospital, Zibo, China.
Ewing sarcoma (ES) is a malignant bone tumor prevalent among children and adolescents. Disulfidptosis represents a novel form of cell death; however, the mechanism of disulfidptosis in ES remains unclear. Our aim is to explore the disulfidptosis-related prognostic signature in ES.
View Article and Find Full Text PDFA fatal case of peritonitis due to colonic localization of acute myeloid leukemia.
Ann Hematol
January 2025
Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
Myeloid sarcoma (MS) is an extramedullary localization of immature granulocyte cells that can occur in association with acute myeloid leukemia (AML). Gastrointestinal involvement is relatively common in MS, but exclusive colonic localization is a rare occurrence. Here, we report on a 53-year-old male patient affected by AML developing a severe abdominal pain caused by intestinal perforation requiring surgical intervention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!